WuXi XDC Cayman's gross profit for the
three
months ended in Jun. 2023 was HK$121 Mil. WuXi XDC Cayman's gross profit for the trailing twelve months (TTM) ended in Jun. 2023 was HK$256 Mil.
Gross Margin % is calculated as gross profit divided by its revenue. WuXi XDC Cayman's gross profit for the
three
months ended in Jun. 2023 was HK$121 Mil. WuXi XDC Cayman's Revenue for the
three
months ended in Jun. 2023 was HK$553 Mil. Therefore, WuXi XDC Cayman's Gross Margin % for the quarter that ended in Jun. 2023 was 21.95%.
WuXi XDC Cayman had a gross margin of 21.95% for the quarter that ended in Jun. 2023 => Competition eroding margins
During the past 4 years, the highestGross Margin % of WuXi XDC Cayman was 36.48%. The lowest was 8.39%. And the median was 26.36%.
WuXi XDC Cayman Gross Profit Historical Data
The historical data trend for WuXi XDC Cayman's Gross Profit can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of WuXi XDC Cayman's Gross Profit
For the Diagnostics & Research subindustry, WuXi XDC Cayman's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
WuXi XDC Cayman's Gross Profit Distribution in the Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, WuXi XDC Cayman's Gross Profit distribution charts can be found below:
* The bar in red indicates where WuXi XDC Cayman's Gross Profit falls into.
WuXi XDC Cayman Gross Profit Calculation
Gross Profit is the different between the sale prices and the cost of buying or producing the goods.
WuXi XDC Cayman's Gross Profit for the fiscal year that ended in Dec. 2023 is calculated as
Gross Profit for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was HK$256 Mil.
Gross Profit is the numerator in the calculation of Gross Margin.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
WuXi XDC Cayman had a gross margin of 21.95% for the quarter that ended in Jun. 2023 => Competition eroding margins
WuXi XDC Cayman Gross Profit Related Terms
Thank you for viewing the detailed overview of WuXi XDC Cayman's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.
No. 11 Xinhui Ring Road, Xinwu, Jiangsu, Wuxi, CHN
Website
WuXi XDC Cayman Inc is a leading CRDMO focused on the global ADC and broader bioconjugate market and the only one dedicated to providing integrated and end-to-end services. Leveraging expertise in both biologics and small molecules, It offers interdisciplinary and comprehensive services, covering bioconjugate discovery, research, development and manufacturing. The company provides these services from proximately located, state-of-the-art laboratories and manufacturing facilities, leading to the significant reduction of development timeline and costs. As a fully integrated one-stop bioconjugate discovery, development and manufacturing platform, its mission is to continuously enhance its platform, and propel and transform the development of the bioconjugate industry.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
HKSE:02268 has been successfully added to your